Press "Enter" to skip to content

That ought to follow in coming weeks.

ACT’s hESC-derived RPE cells receive EMA positive opinion for Orphan Medication Designation for Stargardt’s disease Advanced Cell Technology, Inc. This opinion shall today end up being forwarded by the EMA to the European Commission for his or her adoption, that ought to follow in coming weeks. We are extremely pleased to receive this positive opinion for Orphan Drug Designation from the EMA for our hESC-derived RPE cells for the treating Stargardt’s disease, said Gary Rabin, ACT’s interim chairman and CEO . There happens to be no authorized treatment for Stargardt’s disease, and we will work to move this European trial forward as quickly as possible diligently. ..

‘Further research is necessary but this indicates that ADAMTS7 would be a promising target against which new medications could be designed to act.’.. ADAMTS7 enzyme plays a crucial role in cardiovascular system disease Researchers investigating how certain genes affect an person's risk of developing cardiovascular system disease possess identified a new therapeutic target, according to analyze published today in The American Journal of Human Genetics. They have discovered that an enzyme known as ADAMTS7 plays an essential role in the build-up of cells in the coronary arteries which result in coronary heart disease. Cardiovascular system disease may be the country's biggest killer, with around 94,000 deaths in the UK each year.